Compare Amylx Pharmaceuticals Inc (AMLX) vs Waste Management, Inc. (WM) Price & Performance

AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.

The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.

WM trades at $233.33, up 0.72% today, showing steady performance near its 52-week high. The stock maintains a bullish technical signal with strong moving average support. Fundamentally, revenue grew to $25.20B in 2025 with a net income margin of 10.99%, though recent quarters show mixed earnings results. Analyst consensus remains positive with a $263.57 price target. The company continues its dividend payments, with the next $0.95 dividend scheduled for June 2026.

Outlook: WM's defensive business model and pricing power provide stability, but elevated valuation ratios (P/E 33.77) pose risks if growth slows. Upside potential exists if the company meets Q2 2026 earnings expectations. Key risks include debt levels and economic sensitivity. Wall Street's strong buy sentiment (57% buy ratings) supports a cautiously optimistic view.